secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001628280-23-015695
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Q1 net loss narrows to $9.955M; cash $16.7M; AVTX-002 topline due Q2 2023
-------------------------------------------------------------------------------

- Net loss $9.955M ($0.85/share) vs $22.051M ($2.35) in Q1 2022; revenue $475K down from $1.173M.
- Cash and equivalents $16.687M at March 31, 2023, up $3.515M from Dec 31, 2022 due to $13.7M equity financing.
- Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma completed enrollment (91 patients); topline data expected Q2 2023.
- Operating expenses cut to $9.267M from $22.026M, driven by cost savings initiatives implemented in Q1 2022.
- AVTX-008 lead molecule identified; IND submission planned for 2024. AVTX-803 LADDER trial timing under evaluation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023015695/0001628280-23-015695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023015695/avtx-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer